Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.
You may also be interested in...
Just-Approved Cimzia Set To Enter Tough RA Market
UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.
Just-Approved Cimzia Set To Enter Tough RA Market
UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.
Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies